alexa Psychobiotics; A Promise for Neurodevelopmental Therapy | OMICS International
ISSN: 2329-8901
Journal of Probiotics & Health
Like us on:
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Psychobiotics; A Promise for Neurodevelopmental Therapy

Eric Banan-Mwine Daliri1, Deog H Oh1 and Byong H Lee2*
1Department of Food Science and Biotechnology, Kangwon National University, Chuncheon, South Korea
2Department of Microbiology/Immunology, McGill University, Montreal, QC, Canada
*Corresponding Author : Byong Lee
Department of Microbiology/Immunology
McGill University, Montreal, QC, Canada
Tel: +821047799808
E-mail: [email protected]
Received date: Feb 10, 2016; Accepted date: Apr 04, 2016; Published date: Apr 11, 2016
Citation: Daliri EBM, Deog H, Lee BH (2016) Psychobiotics; A Promise for Neurodevelopmental Therapy. J Prob Health 4:146. doi:10.4172/2329-8901.1000146
Copyright: © 2016 Daliri EBM, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Probiotics & Health

Abstract

The inseparable association between man and microbes has long been known and some of their benefits are well documented. However, the use of bacteria as therapeutics has attracted much interest. Much is known about the ability of gut microbes to enhance immunity, lower cholesterol levels, improve gut barrier functions and many more benefits. Although it is evident that the gut and brain communicate through biochemical signaling which often involves the gut microbiota, it is still not clear whether or not gut manipulations through probiotic administration can correct or treat neurological problems. Many studies have shown that patients with neurodegenerative diseases also have gut dysbiosis and other studies have also shown the ability of certain gut bacteria to synthesize neurotransmitters. Yet, do these probiotics produce enough neuroactive chemicals to influence physiology? Are there precautions to be taken, since such probiotics may cause undesirable effects? This review discusses our current knowledge on the ability of probiotics to affect the central nervous system (CNS) and their potential use in neurodegenerative therapy. Some knowledge gaps left in this area of research have also been highlighted.

Keywords
Probiotics; Gut dysbiosis; Psycho probiotics; Neurodegenerative therapy
Introduction
Microbes are ubiquitous as they are found everywhere on the planet. It is therefore not surprising that the human body is made of 90% bacteria cells and only 10% human cells making us a cocktail of human and bacteria cells tightly associated in a mutualistic relationship [1]. These microbes may play very essential roles in the development of the fetus and that may be why they are present in amniotic fluids, amniotic cord blood, and even in healthy neonatal meconium [2,3]. The human gut microbiome (the collection of all the microorganisms living in association with the human gut) consists of three enterotypes namely, Bacteroides (most abundant and most variable genus), Prevotella and Ruminococcus [4]. Over 1500 gut bacteria species are present in the human body [5] with more than 95% of them residing in the gut [6]. These bacteria contain over 8 million distinct genes encoding for several enzymes and proteins which influence host metabolism. A balance in the richness of the gut bacteria is therefore required for homeostasis. In various pathological conditions such as chronic anxiety, depression, autism and celiac disease [7,8], disease-associated dysbiosis are characterized by an imbalance in the levels, the reciprocal abundance, the presence and/or localization of normal gut bacteria species, rather than an overgrowth of well-defined pathogenic bacteria (as observed in C. difficile infection). Such disease-associated alterations in the microbiome are usually caused by genetic and environmental factors such as drugs, diet, toxins and pathogens [9]. Over the years, studies with germ free (GF) mice have shown that majority of the biochemical compounds and metabolites circulating in the blood are as a result of the gut microbial activities and these compounds affect mammalian behavior and endocrine response [10]. Heijts et al. [11] observed that early microbial colonization process was required to initiate brain signaling mechanisms that affect neuronal circuits involved in motor control and anxiety in mice. Their study shows the role of gut microbes in the normal mammalian brain development. Strong associations between microbial pathogenic infections and neurodevelopmental disorders such as autism and schizophrenia during perinatal periods have also been reported [12]. Many other studies have shown interesting correlations between emotional state and gut functionality [13,14] and the gut bacteria have been implicated in this process. Therefore, the strong association between gut dysbiosis, intestinal permeability and neurological dysfunction suggests that modifying the gut microbiota may provide a promising therapeutic option in emotional and neurodegenerative ailments. The search for probiotics that can affect cognitive functions has therefore increased recently. Such probiotics are called psychobiotics. Dinan et al. [15] defined psychobiotics as live organisms that when ingested in adequate amounts produce beneficial health effects to patients suffering from psychiatric illness. This work highlights how the gut microbiota and the brain interact and how this knowledge may be helpful in the treatment and management of diseases associated with the central nervous system (CNS).
The gut–brain communication pathway
The gut is embedded with neurons of the enteric nervous system, a subdivision of the autonomic nervous system that directly controls the gastrointestinal tract. During early embryogenesis, a neural crest is formed which latter differentiates into the enteric nervous system and the CNS [16]. These two systems are later connected by the vagus nerve (the tenth cranial nerve that runs from the brain stem down to the abdomen) during development [17]. To control gut activity patterns, the brain sends signals through command neurons to the vagus nerve which regulates the volume of signals and relays the signal to the gut interneurons in a bidirectional fashion. This is made possible by the abundance of command neurons and interneurons in the myenteric plexus and submucosal plexus of the gut. The plexus contain glial cells, mast cells and sensory nerve endings for monitoring digestion and sending feed signals back to the spinal cord and the brain [18]. The enterochromaffin (EC) cells in the intestinal mucosa produce about 90% of the body’s serotonin [19] and this brain neurotransmitter is thought to affect behaviors such as appetite, emotional, motor, cognitive and autonomic behaviors [20]. However, germ-free mice produce low levels of serotonin (about 60% lower than conventional mice) but increased levels of serotonin are observed when the mice are recolonized with normal gut microbes implying the impact of gut microbes on the production of the neurotransmitter [21]. This indicates how gut microbes communicate with the brain to affect physiology that shows the interesting prospects of using probiotics to restore brain function associated disorders in patients.
Gut dysbiosis and neuropathology
Many CNS disorders are associated with dysbiosis in the gut resulting in gastrointestinal disturbance [22]. Autism spectrum disorder (ASD) is a developmental disability that can cause significant social, communication and behavioral challenges caused by a combination of genetic and environmental risk factors. Gastrointestinal disturbances are common among children with ASD. The genera Prevotella, Coprococcus, and unclassified Veillonellaceae were significantly reduced in autistic children with high levels of Enterobacteriaceae [23]. They also have increased levels of Ruminococcus torques [24] which degrade mucus in the gut to induce gut barrier dysfunction. Children with autism also have higher levels of Clostridium species relative to healthy subjects [25]. Ileal and caecal mucosa biopsy specimens of children diagnosed with autism and gastrointestinal dysfunction contain Sutterella species but the bacteria were absent in children with only gastrointestinal dysfunction [2,26]. This finding reveals a potential role of Sutterella species in autism disorder but their actual role in the pathogenesis of the disease is still unknown. Parkinson's disease (PD) is another disease that has been linked with gut dysbiosis. Neurodegeneration in PD results from both genetic and environmental factors. These factors result in the progressive impairment or deterioration of neurons in the substantia nigra of the brain that produce dopamine. The decrease in dopamine levels results in abnormal brain activity. Meanwhile, as most PD patients usually experience constipation several years before the onset of the motor symptoms, that could show a possible link between gut dysbiosis and the brain in the pathogenesis of the disease [27]. Patients with PD have shown to have significantly higher levels of putrefaction bacteria such as Proteus and Klebsiella species in their small intestine and this contributes to the high urinary indoxyl sulfate concentrations in PD patients relative to healthy controls [28,29]. Furthermore, they have reduced Prevotellaceae significantly and increased Enterobacteriaceae with positively associated with the severity of postural instability and gait difficulty [28,30]. In fact, the presence of Prevotella in the human gastrointestinal tract is inversely correlated with PD. Members of the genus Prevotella synthesize mucin, thiamine and folate as well as neuroactive short chain fatty acids [28]. A reduction in these bacteria therefore indicates a compromise in gut epithelial integrity due to low mucin synthesis, thereby enhancing gut permeability and systemic exposure to bacteria endotoxins [31]. Another disease thought to be linked with gut dysbiosis is celiac disease. The disease is an autoimmune disorder triggered by dietary gluten in genetically susceptible individuals. However, environmental factors such as infections may trigger changes in the gut of people who have such genes that make them more prone to abnormal immune response when consumed gluten. Many celiacs (up to 50%) develop peripheral neuropathy, ataxia, epilepsy (in some children) and even dementia in adults [32]. Celiac disease in children is usually preceded by gastroenteritis that suggests the involvement of gut microbes in the genesis of the disease [8]. Analyses of the duodenal microbiota of children with celiac disease revealed significant abundance of Bacteroides and E. coli and a significant reduction in Lactobacillus and Bifidobacterium compared to healthy controls [33]. It is thought that the presence of high levels of Gram-negative and potentially proinflammatory bacteria in the duodenum of celiac children might contribute to the symptoms of the disease that could favor the pathological process [34,35]. Meanwhile, other studies have proposed that alterations in the gut mucosal glycosylation in some celiacs can cause changes in the bacterial flora which might lead to a functional change in the gut [8]. It is therefore not clear whether celiac disease is caused by the abnormal glycosylation of the gut mucosa or it is the changed microbiota that triggers the abnormal glycosylation of the gut. However, since most patients with neuropathological cases including cerebral palsy, chronic depression and Rett syndrome experience gastrointestinal disorders, that may be linked with the gut bacteria [36-38].
Psycobiotics and neurodegenerative therapy
Many gut bacteria have been found to synthesize and respond to neuroactive compounds similar to those produced in the host and this gives a clue to the point where the two kingdoms (prokaryotae and animalia) communicate [39]. One such biologically active compound is γ-aminobutyric acid (GABA), a brain neurotransmitter that suppresses anxiety and depression [40]. Human intestinally derived strains of Lactobacillus brevis DPC6108 and Bifidobacterium dentium have been shown to produce large amounts of GABA when cultured in media containing monosodium glutamate [41]. The ability of these intestine bacteria to synthesize neurochemicals shows that the balanced gut microbes in healthy people regulate GABA levels to ensure homeostasis while dysbiosis can be traced a deficiency in this neurotransmitter causing depression. Indeed, depressed patients have been found to have significantly low levels of GABA in their cerebrospinal fluid [42] as well as in their prefrontal, dorsolateral, and occipital cortex [43]. To study the ability of probiotics in preventing depression in humans, Steenbergen et al. [44] administered a multispecies probiotic containing Lactobacillus brevis W, Bifidobacterium lactis W, Lactobacillus acidophilus W37, Bifidobacterium bifidum W2, Lactobacillus salivarius W2, Lactobacillus casei W5, and Lactococcus lactis (W19 and W58) to 20 healthy individuals while the control group received a placebo for 4 weeks. After 4 weeks, the consumers of the probiotics showed a significant overall reduction in the cognitive reactivity to sad mood. Studies on the ability of probiotics to treat patients with depression and anxiety are however needed to validate this claim. Another symptom associated with depression is the alteration in the expression of central GABA receptor mRNA [45]. Interestingly, probiotic Lb. rhamnosus (JB-1) appeared to reduce the levels of stress-induced corticosterone and increase GABAAα2 receptor mRNA expression in the hypothalamus while reducing the expression of GABAAα2 receptor mRNA in the amygdala and prefrontal cortex in animal models [46] causing a reduction in stress. These researchers assumed that Lb. rhamnosus (JB-1) may influence brain and behavior by facilitating vagal firing [47]. Though the study showed how probiotics may affect mood and behavior, it is possible that other neurotransmitter systems and/neuropeptides may also be involved in the reduction of anxietylike behavior and not just the regulation of the GABA receptors.
Other probiotics are known to modulate the production of serotonin in the brain. Serotonin synthesis in the brain depends on the levels of tryptophan and some probiotics have been found to elevate the levels of serum tryptophan [48]. Low serotonin levels have been linked with depression and hence probiotics that elevates tryptophan synthesis may potentially enhance serotonin synthesis. Chronic administration of Bifidobacteria infantis to rats has shown to increase plasma tryptophan levels relative to control groups and the increased tryptophan levels affect central neurochemical functions [49]. This phenomenon may account for why Rao et al. [48] observed a significant reduction in anxiety scores compared to controls after orally administering Lactobacillus casei strain Shirota to 39 patients with chronic fatigue syndrome for 2 months. Since these researchers did not examine the bowel functions during the study despite an increase in fecal Lactobacillus and Bifidobacteria levels, it is possible that the reduced anxiety was due to an improvement in bowel functions.
Another means by which probiotics affect mood is their ability to modulate pain in the gut. Oral administration of Lactobacillus acidophilus has shown to reduce pain by inducing opioid and cannabinoid receptors in the intestinal epithelial cells [50]. The opium and cannabinoid systems are involved in mood regulation, pain, reward and addictive behavior [51]. Mice lacking mu-opioid receptors do not exhibit morphine analgesic and addictive behaviors as compared with the wild type mice [52]. The ability of Lactobacillus acidophilus to induce opioid and cannabinoid receptors therefore opens new doors to enhancing pain relief in diseases associated with compromised gut epithelial barrier functions such as IBD through probiotic supplementation.
Conclusion
Although there is growing evidence to show the potential of probiotics to treat depression, anxiety and even improve symptoms associated with autism in animal models, their mechanisms of action and duration of the health effects are still not clearly understood. This information is important because many of the ingested probiotics pass out in feces and it is unclear whether they would leave lasting effects or the therapy (probiotic consumption) would have to be continued forever. In fact, the ability of probiotics to synthesize neuroactive compounds make them potential delivery vehicles for neurodevelopmental therapy as Lyte proposed. However, do these consumed probiotics produce significant amounts of neurochemicals capable of causing any physiological effect in humans? The consumption of fermented foods date back to centuries and many fermented foods contain neuroactive compounds from some of these psycobiotics, however very little is known about the ability of these foods to treat neurodegenerative diseases or have any impact on mood. Much more human studies are therefore needed to substantiate the psychoactive ability of probiotics. It will also be helpful to know whether the entry of tryptophan produced by probiotics into brain is really related to the synthesis of serotonin. Further studies are also needed to better understand how gut bacteria induce EC cells to produce serotonin as observed by Yano et al. [21].
References
Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Recommended Conferences

Article Usage

  • Total views: 8909
  • [From(publication date):
    April-2016 - Dec 16, 2017]
  • Breakdown by view type
  • HTML page views : 8711
  • PDF downloads : 198
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version